Title : Metformin in combination with rosiglitazone contribute to the increased serum adiponectin levels in people with type 2 diabetes mellitus.

Pub. Date : 2017 Sep

PMID : 28962190






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Metformin in combination with rosiglitazone contribute to the increased serum adiponectin levels in people with type 2 diabetes mellitus. Rosiglitazone adiponectin, C1Q and collagen domain containing Homo sapiens
2 To evaluate how metformin plus rosiglitazone affect serum adiponectin levels in people suffering from type 2 diabetes mellitus (T2DM), 240 patients having T2DM were selected in this cohort study. Rosiglitazone adiponectin, C1Q and collagen domain containing Homo sapiens
3 Further subgroup analyses indicated that combination therapy of metformin and rosiglitazone may increase the amount of serum adiponectin in T2DM sufferers among the majority subgroups (all P<0.05). Rosiglitazone adiponectin, C1Q and collagen domain containing Homo sapiens
4 The combination of metformin and rosiglitazone treatment increased serum adiponectin levels, suggesting that metformin plus rosiglitazone therapy is a suitable choice to treat T2DM. Rosiglitazone adiponectin, C1Q and collagen domain containing Homo sapiens
5 The combination of metformin and rosiglitazone treatment increased serum adiponectin levels, suggesting that metformin plus rosiglitazone therapy is a suitable choice to treat T2DM. Rosiglitazone adiponectin, C1Q and collagen domain containing Homo sapiens